Galectin-3 Expression in Colorectal Cancer: Relation to Invasion and Metastasis
Background: Galectin-3, a β-galactoside-binding protein, has been associated with various biological processes, such as cell adhesion, recognition, proliferation, differentiation and apoptosis. The aim of this study was to determine the relationship of galectin-3 expression to clinicopathological f...
Gespeichert in:
Veröffentlicht in: | Anticancer research 2007-07, Vol.27 (4B), p.2289-2296 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Background: Galectin-3, a β-galactoside-binding protein, has been associated with various biological processes, such as cell
adhesion, recognition, proliferation, differentiation and apoptosis. The aim of this study was to determine the relationship
of galectin-3 expression to clinicopathological findings in patients with colorectal cancer. Furthermore, the correlation
between the expression of galectin-3 and β-catenin, and the Ki-67 labeling index were investigated. Materials and Methods:
Immunohistochemical assessment of galectin-3, β-catenin and Ki-67 expression was performed on samples from 108 patients with
colorectal cancer. The expression of galectin-3 was classified at the tumor surface and the invasive front, and its relationship
with clinicopathological factors was considered from a statistical viewpoint. Results: There was significant liver metastasis
when the expression of galectin-3 was lower at the invasive front of a tumor compared to its surface (p=0.04). There were
also significant correlations between β-catenin expression at the tumor surface and liver metastasis and tumor stage (p=0.03,
p=0.04 respectively). Conclusion: The reduction of galectin-3 expression is associated with the invasion and metastasis of
colorectal cancer. A possible involvement of galectin-3 expression in tumor invasion, metastasis and proliferation in patients
with colorectal cancer is suggested. |
---|---|
ISSN: | 0250-7005 1791-7530 |